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Abstract:
Introduction:
Rheumatoid Arthritis (RA) is the most common cause of inflammatory polyarthritis. In RA, increased circulating levels of pro-inflammatory
cytokines contribute to the overall symptomatology of fatigue, pain, and joint stiffness. Baricitinib is an orally administered biologic DMARD,
used in RA patients, inhibiting signaling via JAK1/JAK2 inhibition, reducing the release of pro-inflammatory cytokines.
Objective:
To explore the efficacy and tolerability for baricitinib in a local population.
Methods:
A cross-sectional study was carried out to review data of RA patients on Baricitinib from the researchers’ own clinic, since its approval in August
2017. The data was collected from an anonymized electronic patient records report. The clinical response was then classified into mild, moderate,
and significant improvement.
Results and Discussion:
Overall, 27 out of 37 patients (72.9%) showed clinical improvement with baricitinib. In 9(24.3%) out of 37 patients, the dose had to be reduced to
either 2mg/day or 2mg/day - 4mg/day on alternate days. In four of the 9 patients’ where the dose was reduced due to infections (UTI or sinuses),
they subsequently experienced fewer infections while maintaining moderate improvement in their RA.
Conclusion:
There is a need for longer-term and larger studies to evaluate the full side effects profile of baricitinib in the local population.
Keywords: Rheumatoid arthritis, Janus associated kinase, Baricitinib, Conventional disease modifying drugs, Biologic disease modifying drugs,
UTI.
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1. INTRODUCTION
Rheumatoid Arthritis (RA) is the most common cause of
inflammatory polyarthritis. In RA, increased circulating levels
of  pro-inflammatory  cytokines  contribute  to  the  overall
symptomatology  of  fatigue,  pain,  and  joint  stiffness.  [  1  ].
Rheumatoid Arthritis (RA) affects over 1% of the population.
RA  synovitis  affects  the  knees,  ankles,  hips,  and  shoulders,
causing irreversible damage. However, as it progresses, it can
also affect vital organs, such as the heart, lungs, and eyes [2].
Currently, rheumatoid arthritis is diagnosed by a combina-
* Address correspondence to this author at the School of Pharmacy, University of
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tion  of  clinical  presentation,  imaging  and  blood  tests,
Rheumatoid Factor (RF), (less specific to RA), and anti-cyclic
Citrullinated  Peptides  (anti-CCPs,  specific  to  RA).  When  a
patient  with  RA  symptoms  tests  negative  for  the  anti-CCPs,
they may still be diagnosed using radiographic imaging [1].
Methotrexate (MTX), either alone or in combination with
other conventional synthetic disease-modifying antirheumatic
drugs  (cDMARDs),  remains  the  first-line  therapy  [3].
cDMARDs,  such  as  oral  methotrexate,  leflunomide,  or
sulfasalazine,  take  up  to  3  months  to  show  benefit,
necessitating  short-term  glucocorticoid  therapy  to  induce
remission. Approximately one-third of patients do not tolerate
MTX  treatment  [4,  5].  Therefore,  assessing  therapies  in
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development  as  alternatives  to  MTX  is  an  important  part  of
understanding  potential  new  treatments  [6].  When  mono-
therapy fails to maintain remission or has unacceptable adverse
effects,  under  the  UK  guidelines,  the  current  next  stage  is  a
combination of conventional cDMARDs. Only when this has
failed are biological agents considered. Biological agents can
often  provide  effective  monotherapy  where  patients  cannot
tolerate cDMARDS [1].
Multiple  cytokines  are  implicated  in  the  pathogenesis  of
RA  and  their  release  is  partially  mediated  through  the
JAK-1/JAK-2  signaling  pathway.  JAK-1/JAK-2  heterodimer
stimulates  release  of  signaling  molecules  via  a  signal
transduction  pathway  involving  Signal  Transducer  and
Activator of Transcription (STAT) proteins, which ultimately
modulates  gene  expression  in  immunological  cells.  This
modulates  the  release  of  interleukin-6  and  interferons.
Baricitinib  is  an  orally  administered  JAK-1/JAK-2  inhibitor
that has shown efficacy and acceptable safety in patients with
RA  who  had  experienced  an  insufficient  response  to
cDMARDs  or  other  bDMARDs  [  7  -  9].
2. METHODS
This  study  was  conducted  in  two  parts:  a  mini  critical
review  and  a  real-world  retrospective  data  analysis.  The
retrospective data analysis study was considered as a process
improvement audit by the National Health Service (NHS) Trust
local  research  and  development  committee.  Baricitinib  was
approved by the United Kingdom, National Institute for Health
and  Care  Excellence  (NICE)  in  August  2017,  for  use  in
moderate to severe RA in the following group of adult patients,
where [ 10 ]:
RA  has  responded  inadequately  to  intensive  therapy[A]
with a combination of cDMARDs, only if the disease
is severe (a DAS-28 of more than 5.1).
RA has responded inadequately to or who cannot have[B]
other  DMARDs,  including  at  least  one  bDMARD,
only if the disease is severe (a DAS-28 of more than
5.1) and they cannot have rituximab.
Baricitinib  is  used  as  monotherapy  for  people  who[C]
cannot take methotrexate because it is contraindicated
or because of intolerance when the criteria in sections
1 and 2 are met.
To  continue  treatment  only  if  there  is  a  moderate[D]
response  measured  using  European  League  Against
Rheumatism  (EULAR)  criteria  at  6  months  after
starting  therapy.  After  an  initial  response  within  6
months,  withdraw  treatment  if  at  least  a  moderate
EULAR  response  is  not  maintained.
In  this  retrospective  study  of  37  patients  who  received
baricitinib between January 2017 and December 2019, the aim
was to explore the outcome for these real-world RA patients,
classified according to their response to the drug and side effect
profiles experienced in this group of patients.
3. MINI CRITICAL REVIEW
To better understand the safety and efficacy of baricitinib,
compared  to  other  agents  alone  or  in  combination,  such  as
adalimumab and baricitinib, with MTX or placebo, a literature
search was conducted for randomized controlled clinical trials
(Table 1 ).
Taylor et al. (2017) found that baricitinib and adalimumab
were similar in safety in terms of increased infection rates, i.e.,
36%  and  33%,  respectively,  compared  with  slightly  lower
infection risk in the placebo group of 27%. Both medications
were associated with lower levels of neutrophil count and the
increasing  infection  risk.  Both  baricitinib  and  adalimumab
increased  cholesterol  levels,  however,  only  2  patients  in  the
baricitinib  group  and  1  patient  in  the  adalimumab  group
experienced  a  serious  cardiovascular  event.  There  were  five
reported  deaths;  one  was  in  the  placebo  group,  two  in  the
baricitinib  group,  one  in  the  adalimumab group,  and another
patient  in  the  placebo  group  who  received  rescue  treatment
with baricitinib [11, 12]. After week 12, baricitinib appeared
slightly more effective in 70% of the patients on the American
College of Rheumatology (ACR) scale – ACR20 measuring a
20% improvement on the 28 point scale, compared with 61%
for adalimumab and 40% for placebo. In addition, a significant
reduction  in  radiographic  progression  of  structural  joint
damage was observed at weeks 24 and 52 for both baricitinib
and  adalimumab  compared  to  placebo.  The  mean  change  in
disease  Disease  Activity  Score  C-Reactive  Protein  activity
score  (DAS-28-CRP)  at  week  12  (−2.24  for  baricitinib  vs.
−1.95  for  adalimumab)  suggests  that  baricitinib  may  be
superior  to  adalimumab  [13,  14].
Table 1. Summary of clinical trials included.
Study Intervention Baricitinib Dose Duration
(Weeks)
Biologic Naive Number of Participants
6 Baricitinib alone
vs. Baricitinib + Methotrexate
vs. Methotrexate alone










12 Baricitinib vs. placebo 2 mg or 4 mg 24 No (but off biologic for 4 weeks wash
out prior enrolment)
N=527
175 baricitinib 2 mg
175 baricitinib 4 mg
175 placebo
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The addition of oral baricitinib as an add-on-therapy to oral
MTX  was  associated  with  improvements  in  signs  and
symptoms,  physical  function,  patient-reported outcomes,  and
progression of structural joint damage, as compared to placebo.
It was also associated with improvements in ACR-20 response
and  DAS-28-CRP  as  compared  to  adalimumab  [13,  14].
Fleischmann  et  al.  (2017)  and  Genovese  et  al.  (2016)
compared the efficacy of baricitinib to adalimumab, concluding
that  baricitinib  demonstrated  superior  ACR-20  response  and
DAS-28-CRP.  Their  evaluated  end-point  measures,  after
adjustment  for  multiplicity,  included  20%  improvement
according to the criteria of the ACR-20 response (the primary
end point), the Disease Activity Score for 28 joints (DAS-28),
the Health Assessment Questionnaire–Disability Index, and the
Simplified Disease Activity Index at week 12. In addition, the
radiographic progression of joint damage was measured by the
van der Heijde modification of the total Sharp score (mTSS)
(range, 0 to 448, with higher scores indicating greater structural
joint  damage)  at  week  24  [13,  14].  Results  from  the  three
studies are illustrated in Table 2.
4. REAL-WORLD DATA RETROSPECTIVE STUDY
This  retrospective  study included medical  records  for  all
adult  RA  patients  receiving  baricitinib,  managed  by  the
Rheumatology clinics at a District General Hospital in the UK
Midlands.  All  patients  had  been  diagnosed  according  to  the
ACR/EULAR 2010 criteria [ 15 ]. The data was collected using
an  anonymized  electronic  patient  records  report,  which  is
classified  as  a  quality  improvement  process  by  the  hospital
Research  and  Development  committee,  not  requiring  ethical
approval. The demographic data and clinic letters were used to
assess  the  patients’  clinical  responses  to  baricitinib.  Clinical
improvement  was  inferred  from  multiple  descriptors  in  the
clinic records, which included DAS-28 score changes, patient’s
global assessment and/or physician’s global assessments. The
clinical  response  was  classified  into  mild,  moderate,  and
significant  improvement  as  defined  below:
Mild  improvement  was  defined  as  where  a  patient[A]
showed  improvement  in  global  assessment  but  no
major  improvement  in  their  DAS-28  scores  or
physician’s  global  assessment.
Moderate  improvement  was  when  global  assessment[B]
and  physicians’  global  assessment  showed  improve-
ment  in  DAS-28  score  as  per  EULAR  response
criteria.
Significant improvement was when a patient remained[C]
in remission or low disease activity state.
Of the 37 patients’ records reviewed, there were 7(18.9%)
males and 30(81%) females. Age distribution is illustrated in
Fig. (1).
Table 2. Key findings of the trials.
- Study 6 Study 10 Study 11
- Methotrexate* Baricitinib* Combination
methotrexate
Baricitinib*







5.9+1.0 5.9+1.0 5.9+0.9 5.7+1.0 5.8+0.9 5.8+0.9 5.9±0.9 6.0±0.9 5.9±1.0
DAS-28,
ESR












“The ACR20 response rate at week 24 for
baricitinib monotherapy and MTX monotherapy
was
77% and 62%, respectively (P=0.001 for
noninferiority).
Moreover, baricitinib monotherapy was found to
be superior to MTX monotherapy at week 24
(P=0.01)”
“At week 12, the primary ACR20 response
rate for
baricitinib was 70% as compared with 40%
for
placebo (P<0.001). Significant
improvements with baricitinib as compared
with placebo were seen Baricitinib was
found to be significantly superior to
adalimumab (P = 0.01)”
“At week 12, the ACR20 response
rate (primary
end point) was 55% among patients
who received
baricitinib at a dose of 4 mg, as
compared
with 27% among those who received
placebo
(P<0.001. The 2-mg dose of
baricitinib was not compared with
placebo”
*Reported as Means ±SD
**Direct quotation from original publications
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Fig. (1). The age distribution of the patients in this study.
Two patients (5.3%) had been diagnosed with RA between
five and ten years, whilst the majority of patients 34 (92%) had
been diagnosed for more than 10 years and one patient (2.7%)
for  more  than  20  years.  Eight  (21%)  had  no  comorbidities,
while  the  remaining  29  (78%)  had  one  or  more.  Common
comorbidities  were  type  II  diabetes,  Chronic  Obstructive
Pulmonary Diseases (COPD), asthma, secondary osteoarthritis,
osteoporosis,  hypertension,  Crohn’s  disease,  IBS,  Coeliac
disease, Chronic Kidney Disease (CKD), fibromyalgia, anemia,
peptic ulcer disease, recurrent Urinary Tract Infection (UTI),
degenerative  spine  disease,  hypothyroidism,  and  Interstitial
Lung Disease (ILD). Seventeen patients (45%) were on one or
more additional cDMARD.
4.1.  Overall  Impact  and  Efficacy  of  Baricitinib  in  all
Patients with RA
Where baricitinib was added on to a cDMARD or replaced
the cDMARD, 8 (21.6%) reported significant improvement, 17
(45.9%) had moderate improvements, and 3 (8.1%) had mild
improvement. Eight (21.7%) patients stopped treatment due to
side effects and one patient prescribed baricitinib did not start
therapy (2.7%). Consequently,  28 out of 37 patients (72.9%)
showed clinical improvement with baricitinib.
In the 17 patients prescribed with baricitinib added to their
current  cDMARD’s,  5  (29.4%)  demonstrated  significant
improvement, 8 (47%) had moderate improvement, 2 (11.8%)
had mild improvement while 2 (11.8%) patients out of those 17
stopped treatment due to side effects.
In  the  19(51.3%)  patients  who  received  baricitinib  as
monotherapy,  3  (15.8%)  had  significant  improvement,  9
(47.3%)  had  moderate  improvement,  and  1  (5.3%)  had  mild
improvement.  Of  these,  6  patients  (31.6%)  had  to  cease
baricitinib  due  to  side  effects.
The  one  patient  who  received  baricitinib  as  first-line
treatment  had  chronically  abnormal  Liver  Function  Test
(LFT’s)  results  at  the  time  of  diagnosis  and  did  not  wish  to
receive  injections.  All  other  patients  had  been  previously
exposed to one or more conventional or bDMARD’s and had
either found them ineffective or experienced unacceptable side
effects.
4.2. Baricitinib Safety and Side Effect Profile
Side  effects  were  experienced  in  18  (48.7%)  of  patients.
Infections were noted in 10 patients (27%). Recurrent UTI was
the most common, followed by upper respiratory infections and
sinusitis. GI side effects and neutropenia were noted in 3(8.1%)
and  2(5.4%)  cases,  respectively.  One  (2.7%)  of  the  patients
who developed neutropenia and thrombocytopenia was also on
leflunomide  20  mg  daily  while  the  other  patient  had
experienced  neutropenia  with  leflunomide  previously.  One
(2.7%)  of  the  patients  reported  severe  headaches,  which
improved on stopping baricitinib and resumed when baricitinib
was restarted after 6 weeks, hence baricitinib had to be ceased.
Generalized erythematous rash was noted in 2 (5.4%) patients,
and  a  rise  in  serum  cholesterol  was  noted  in  only  1  (2.7%)
patient.
4.3. Tolerability of Baricitinib
Most of the patients in this study tolerated baricitinib well.
The  longest  duration  of  treatment  amongst  the  patients
reviewed was 29 months, while the shortest was 5 days. Out of
the  37  cases,  5  (13.5%)  patients  had  baricitinib  for  >  24
months, 17 (45.9%) had it between 12-24 months, 4 (10.8%)
had  it  for  6-12  months.  Only  10  (27.1%)  received  it  for  <6
months and 1 (2.7%) did not commence therapy. Five out of 37
patients  had  to  discontinue  baricitinib  due  to  recurrent
problems  within  six  months  of  initiation  and  three  patients
discontinued therapy within one month. The main reasons for
discontinuation of Baricitinib within 1 month were as follows:
One of the patients developed neutropenia in 3 weeks[A]
and  low  platelets  after  commencing  baricitinib.  This
was repeated on re-challenge, therefore a decision was
made to stop its administration.
One patient had easy bruising and fatigue after starting[B]
baricitinib and had to stop on the 6th day.
One  patient  developed  lobar  pneumonia  needing[C]
admission within a month. This patient had a similar
problem  with  other  bDMARD’s  like  etanercept,
abatacept,  and  sarilumab.
4.4. Lower Dose of Baricitinib
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2mg/day every day or 2mg/day and 4mg/day on alternate days.
In  four  of  these  nine  patients,  the  reduction  was  due  to
infections  (UTI  or  sinuses),  and  on  the  reduced  dose,  they
experienced fewer infections while still maintaining moderate
improvement  in  their  RA.  One  of  the  patients  experienced
worsening  CKD  and  another  developed  neutropenia  on  the
4mg/day dose but remained stable on a 2 mg/day dose.
5. RESULTS AND DISCUSSION
Baricitinib was effective in  27(72.9%) of  the 37 patients
reviewed, which was similar to the findings in the three papers
reviewed  [6,  11,  12].  This  efficacy  was  similar  to  the  70%
ACR-20 efficacy in RA-BEAM data found by Genovese et al.
(2016)  [12].  In  this  study,  baricitinib  was  used  as  an  add-on
therapy in 17 patients and as monotherapy in 19 patients. When
used  as  a  monotherapy,  12  (63.15%)  had  a  significant  or
moderate response. This correlates well with the RA-BUILD
data, showing 62% ACR 20 response versus placebo [14]. In
the RA-BEYOND study, it  was noted that a reduced dose of
baricitinib  was  associated  with  a  lower  rate  of  serious
infections. It was also found that, out of nine patients in whom
the  dose  was  reduced,  4  (44%)  cases  had  a  lower  rate  of
infections  while  maintaining  the  efficacy  [14].  The  British
National  Formulary  listed  baricitinib  side  effects  as
dyslipidemia, herpes zoster outbreak, increase risk of infection,
nausea,  oropharyngeal  pain,  thrombocytosis,  and  venous
thromboembolism  [16].
Baricitinib was found useful in bDMARD naïve patients as
well as in patients with inadequately treated or refractory RA
with cDMARD. Being available in two strengths provided the
option  of  reducing  the  dose  in  frail  or  elderly  patients  or
patients with CKD, as well as in patients experiencing frequent
infections  or  neutropenia  or  GI  side  effects.  Venous
thromboembolism complications, in this study, were not noted
but  users  need  to  be  aware  of  the  risk  while  following  their
patients  in  the  clinics  due  to  changes  in  lipids  observed  in
patients undergoing baricitinib therapy [17].
CONCLUSION
In the rheumatology clinic population, baricitinib proved as
a  useful  oral  bDMARD,  used  as  monotherapy  or  in
combination with other cDMARD. There is a need for longer-
term and larger studies to evaluate the full side effects profile
of baricitinib, which is the limitation of this study.
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